Puma Biotech (PBYI) Tops Q4 EPS by 95c, Beat on Revenues

Note: EPS may not be comparable

Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of ($1.03), $0.95 better than the analyst estimate of ($1.98). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $20.01 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Endava CFO placed on leave amid accounting probe
• Jefferies Starts Oversea-Chinese Banking Corp Ltd (OCBC:SP) (OVCHF) at Hold